Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, Burt PA, Arance A, Stout R, Thatcher N. White SC, et al. Among authors: middleton mr. Cancer. 2001 Aug 1;92(3):601-8. doi: 10.1002/1097-0142(20010801)92:3<601::aid-cncr1360>3.0.co;2-k. Cancer. 2001. PMID: 11505405 Clinical Trial.
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Danson S, Middleton MR, O'Byrne KJ, Clemons M, Ranson M, Hassan J, Anderson H, Burt PA, Fairve-Finn C, Stout R, Dowd I, Ashcroft L, Beresford C, Thatcher N. Danson S, et al. Among authors: middleton mr. Cancer. 2003 Aug 1;98(3):542-53. doi: 10.1002/cncr.11535. Cancer. 2003. PMID: 12879472 Free article. Clinical Trial.
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. Among authors: middleton mr. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Halbert G, Waller S, McGrath H, Gumbrell L, McElhinney RS, Donnelly D, McMurry TB, Margison GP. Ranson M, et al. Among authors: middleton mr. Clin Cancer Res. 2006 Mar 1;12(5):1577-84. doi: 10.1158/1078-0432.CCR-05-2198. Clin Cancer Res. 2006. PMID: 16533784 Clinical Trial.
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, Protheroe AS, Vasist LS, Williams DD, Bowen C, Kathman SJ, Hodge JP, Dar MM, de Bono JS, Middleton MR. Blagden SP, et al. Among authors: middleton mr. Br J Cancer. 2008 Mar 11;98(5):894-9. doi: 10.1038/sj.bjc.6604264. Epub 2008 Mar 4. Br J Cancer. 2008. PMID: 18319713 Free PMC article. Clinical Trial.
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR. Khan OA, et al. Among authors: middleton mr. Br J Cancer. 2008 May 20;98(10):1614-8. doi: 10.1038/sj.bjc.6604366. Epub 2008 May 13. Br J Cancer. 2008. PMID: 18475294 Free PMC article. Clinical Trial.
237 results